REG - Competition and Mkts - Merger Update - Cochlear Limited/Oticon Medical

Demant A/SAnnouncement

22/06/2023 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV5252Da&default-theme=true

RNS Number : 5252D  Competition and Markets Authority  22 June 2023

FOR IMMEDIATE RELEASE:  07.00 22 JUNE 2023 

 

CMA ACTION PROTECTS OUTCOMES FOR HEARING IMPLANT PATIENTS

CMA partially prevents sale of hearing implant business after concluding
patients potentially worse off

The Competition and Markets Authority (CMA) has prevented part of a merger
between two of the biggest players in the UK's hearing implant sector. This
action will avoid worse outcomes for patients, who rely on these life-changing
hearing implants, and higher prices for the NHS, which ultimately funds the
cost of these products for patients.

 

The proposed merger of Cochlear Limited (Cochlear) and Oticon Medical, the
hearing implants division of Demant A/S (Demant), was referred for an in-depth
Phase 2 investigation, led by an independent inquiry group, in December
2022.

 

The investigation has found that the merger may lead to a substantial
lessening of competition in bone conduction solution (BCS) products. BCS
products are implants that bypass the damaged parts of the ear, converting
sounds into vibrations that are sent directly to the inner ear.

 

The CMA's final report on the merger concluded that:

·      The deal would eliminate a major BCS competitor from the market,
leaving the merged businesses holding a market share of more than 90 per
cent.

·      Competition from the one remaining BCS competitor and other hearing
solutions would not be sufficient to offset the impact of the deal on
competition.

·      The prospect for market entry from new players or market expansion
by smaller competitors is limited, and not sufficient to prevent competition
concerns.

The loss of competition in BCS products that the Merger would bring could
result in patients who need these hearing implants losing out with less
choice, reduced quality, or less innovation, as well as the NHS, the main
buyer of BCS products in the UK, potentially paying higher prices.

 

To address these concerns, the CMA's independent inquiry group has prohibited
the sale of Oticon Medical's BCS business to Cochlear. Demant will instead
retain its BCS business, which it will continue to run in competition with
Cochlear.

 

The CMA also looked at the impact on the supply of another type of hearing
implants (cochlear implants (CI)) at an earlier phase of investigation but
found no competition concerns in that sector. The CMA found that the CI and
BCS business are largely operated separately today, so can be split up without
reducing their competitiveness, enabling the sale of Oticon Medical's CI
business to Cochlear to go ahead.

 

The CMA's decision followed the consideration of a wide range of evidence,
including concerns raised by clinics, who prescribe these products to
patients, and other market participants.

 

Kip Meek, chair of the independent panel of experts conducting this
investigation, said:

 

"Our primary concern is the well-being of patients. We found that the full
merger could reduce innovation and quality and potentially cost the NHS more
through higher prices.

 

"We're pleased to find a solution which not only addresses these competition
concerns but is also less onerous than preventing the merger entirely."

 

The CMA will now oversee the separation of the business and will take steps to
implement its remedy decision within 12 weeks.

 

For more information, visit the Cochlear/Oticon Medical merger inquiry page.
(https://www.gov.uk/cma-cases/cochlear-slash-oticon-merger-inquiry)

 

Notes to Editors:

1.   Cochlear (Cochlear Limited) manufactures and supplies hearing devices
used by healthcare professionals to treat a range of types of hearing loss,
with a particular focus on cochlear implants (CI) and BCS (together, hearing
implants).

2.   Demant (Demant A/S) develops, manufactures, and supplies hearing
implants (both CI and BCS) through Oticon Medical. Demant also supplies
hearing aids, operates clinics providing hearing care solutions, and supplies
hearing diagnostic products and audio solutions for enterprise, gaming, and
air traffic control.

3.   BCS products are used in the treatment of conductive, mixed, and
single-sided hearing loss. They bypass damaged parts of the ear by using a
sound processor that converts sounds into vibrations that are sent directly to
the inner ear. There are two types of BCS products: passive and active. They
differ in the way they connect the transducer (that translates sounds into
vibrations transmitted through the bone) to the sound processor.

4.   The CMA has outlined its strategic commitment to ensuring its
intervention and remedies take into account those people who may need
particular help to be protected from harm. This commitment sits alongside our
core work on mergers to ensure that everyone can be confident that they are
getting a fair deal. Please read Section 5.6 of our Annual Plan 2023/ 2024
(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1146961/A_CMA_ANNUAL_PLAN_2023-2024_.pdf)
 

5.   All media enquiries should be directed to the CMA press office by email
on press@cma.gov.uk (mailto:press@cma.gov.uk) , or by phone on 020 3738
6460.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MERFZGZVFMRGFZZ